Nuvilex (NASDAQ:PMCB – Get Free Report) and Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.
Risk & Volatility
Nuvilex has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Nuvilex and Enlivex Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvilex | 1 | 0 | 0 | 0 | 1.00 |
| Enlivex Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Valuation & Earnings
This table compares Nuvilex and Enlivex Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvilex | N/A | N/A | $30.66 million | ($1.12) | -0.65 |
| Enlivex Therapeutics | N/A | N/A | $1.24 billion | ($0.55) | -1.05 |
Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nuvilex and Enlivex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvilex | N/A | 2.13% | 1.69% |
| Enlivex Therapeutics | N/A | 248.08% | 206.39% |
Institutional and Insider Ownership
34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Enlivex Therapeutics beats Nuvilex on 9 of the 11 factors compared between the two stocks.
About Nuvilex
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
